Alamgeer M, Pick A, Ramdave S, Joshi P, Kumar B, Ganju V, Prodanovic Z, Watkins N. P3. 03-025 Investigating Phenotypic and Genomic Heterogeneity in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 2017 Jan 1;12(1):S1359-60.
Alamgeer M, Briggs P, Markman B, Midolo P, Watkins N, Kumar B, Ganju V. P1. 07-004 Updated Analysis of Phase II Study of HA-Irinotecan, a CD44-Targeting Formulation of Hyaluronic Acid and Irinotecan, in Small Cell Lung Cancer. Journal of Thoracic Oncology. 2017 Jan 1;12(1):S697-8.
Chan, David, Diego Ferone, Manuela Albertelli, Eva Segelov , and Simron Singh. “Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review.” (2017): 422-422.
Singh, Simron, David Lok Hang Chan, Lesley Moody, Sarah Carsley, David C. Metz, Jonathan R. Strosberg, and Eva Segelov. “Development of follow up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETS): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS).” (2017): 224-224.
Desai, J., Gan, H., Barrow, C., Jameson, M.B., Solomon, B., Atkinson, V., Haydon, A., Millward, M., Begbie, S., Brown, M. and Markman, B., 2017. Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors.
Shaheen, Montasser, Ben Markman, Michael Carducci, Sara Hurvitz, Daruka Mahadevan, Dusan Kotasek, Oscar Goodman et al. “Abstract CT045: Phase 1, open-label, first-in-human study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors.” (2016): CT045-CT045.
Yen CJ, Markman B, Chao Y, Hill A, Kang J, Wang L, Li K, Qi Q, Wu Z, Gan H. P-140Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC). Annals of Oncology. 2017 Jun 1;28(suppl_3).
Desai, Jayesh, Ben Markman, Sumitra Ananda, Niall C. Tebbutt, Michael Michael, Benjamin J. Solomon, Grant A. McArthur et al. “A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.” (2017): 3557-3557.
Friedlander, Michael, Tarek Meniawy, Ben Markman, Linda R. Mileshkin, Paul R. Harnett, Michael Millward, Joanne Lundy et al. “A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.” (2017): 3013-3013.
Chu, QS-C., B. Markman, N. Leighl, L. Krug, C. Rudin, D. Lathers, P. Basciano et al. “A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy.” (2016): 1427PD.
Wang H, Markman B, de Souza P, Dees EC, Gangadhar TC, Piha-Paul SA, Zamboni WC, Murphy C, Senderowicz A. A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies. Annals of Oncology. 2016 Oct 1;27(suppl_6).
Zamboni, William C., Ben Markman, Paul De Souza, E. Claire Dees, Tara Gangadhar, Scott Eliasof, Curran Murphy, Adrian Senderowicz, and Hongwei Wang. “Pharmacokinetics (PK) of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing the payload docetaxel, in patients with refractory solid tumors.” (2016): 2047-2047.
Desai, Jayesh, Ben Markman, Shahneen Kaur Sandhu, Hui Kong Gan, Michael Friedlander, Ben Tran, Tarek Meniawy et al. “A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.” (2016): 3066-3066.
McKeage, Mark James, Brett Gordon Maxwell Hughes, Ben Markman, Manuel Hidalgo, Michael Millward, Michael B. Jameson, Dean Laurence Harris et al. “A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in patients (pts) with 1st line non-squamous NSCLC.” (2016): 9023-9023.
Markman, Ben, Paul L. De Souza, Elizabeth Claire Dees, Tara C. Gangadhar, Adam Cooper, Aflah Roohullah, Vishal Boolell et al. “A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.” (2016): 2526-2526.
Markman B, Serra V, Tabernero J. mTOR Inhibition Beyond Rapalogs. InmTOR Inhibition for Cancer Therapy: Past, Present and Future 2016 (pp. 251-275). Springer Paris.